©2024 Stanford Medicine
Botulinum Toxin Injection for Functional Popliteal Artery Entrapment Syndrome
Not Recruiting
Trial ID: NCT03631966
Purpose
Failure to adequately diagnose and treat patients with functional popliteal artery entrapment
syndrome (PAES) leads to continued pain, loss of function and poor quality of life for many
patients nationwide. Currently, the primary treatment for functional PAES involves muscle
resection, sometimes involving large segments of muscle, which itself can lead to functional
impairment. As such, a less invasive treatment for functional PAES is desirable. The focus of
this work is to determine whether Botulinum toxin type A (BTX-A) injections into the
gastrocnemius muscle can lessen the mechanical forces placed on the popliteal artery by the
involved muscle, thereby improving symptoms caused by impaired distal blood flow.
Official Title
Can Botulinum Toxin Injection Relieve Pain and Improve Function in Patients With Functional Popliteal Artery Entrapment Syndrome?
Eligibility
Inclusion Criteria:
- To participate in the intervention portion of the study, patients must have a
confirmed diagnosis of functional PAES.
- Patients must report ongoing leg pain during or after physical activity at the time of
intervention.
- Patients must have failed prior conservative treatment and have been experiencing
exertional leg pain for > 6 months.
- Patients must be between the age of 18 and 50.
Exclusion Criteria:
Any subject will be excluded from the study if he/she has any of the following:
- History of muscle/tendon ruptures to the lower extremities
- History of a neurological disease that would affect running or jogging
- History of adverse reactions to BTX-A
- Concomitant diagnosis of exertional compartment syndrome or other cause for leg pain.
Intervention(s):
drug: Dysport
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305